Results 121 to 130 of about 22,784 (283)

Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim This study evaluated the efficacy and safety of empagliflozin 10 and 25 mg compared to placebo as add‐on treatment for people with type 2 diabetes mellitus (T2DM) uncontrolled after ≥8 weeks of treatment with metformin and sitagliptin. Materials and Methods A randomised, double‐blind, multicentre, therapeutic confirmatory, phase 3 clinical
Seung‐Hwan Lee, Kyung Ah Han, Eun‐Gyoung Hong, Jun Goo Kang, Choon Hee Chung, Jong Chul Won, Eon Ju Jeon, Jung‐Hwan Cho, Ho Chan Cho, Sin Gon Kim, Eun Seok Kang, So Hun Kim, Hae Jin Kim, In‐Kyung Jeong, Sung Wan Chun, Young Min Cho   +15 more
wiley   +1 more source

Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes. [PDF]

Front Endocrinol (Lausanne), 2021
Liu X, Liu Y, Liu H, Li H, Yang J, Hu P, Xiao X, Liu D.   +7 more
europepmc   +1 more source

Effects of age and disease duration on the glycaemic outcomes and safety of insulin glargine 300 U/mL in people with type 2 diabetes in China: A post‐hoc analysis of the INITIATION study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate the glycaemic outcomes and safety of insulin glargine 300 U/mL (Gla‐300) in Chinese people with uncontrolled type 2 diabetes (T2D) by baseline age and disease duration. Materials and Methods INITIATION was a 24‐week, interventional, single‐arm study where adults with T2D (glycated haemoglobin [HbA1c] 7.5%–11.0%) received Gla ...
Liming Chen, Qiu Zhang, Binhong Duan, Xiaohong Wu, Hailong Wan, Binhong Wen, Jie Han, Haixia Liu, Caixian Yang, Weiwei Liu, Qin Du, Lei Kang, Minlu Zhang   +12 more
wiley   +1 more source

Efficacy and safety of bi-weekly cofrogliptin treatment replacing daily dipeptidyl peptidase-4 inhibitors in Chinese patients with type 2 diabetes mellitus: A multicenter, open-label, randomized controlled phase 2 trial. [PDF]

Diabetes Obes Metab
Abstract Aim This study aimed to investigate the efficacy and safety of bi‐weekly cofrogliptin treatment as a replacement for daily dipeptidyl peptidase‐4 inhibitors (DPP‐4is) in Chinese patients with type 2 diabetes mellitus (T2DM). Methods This multicenter, open‐label, randomized controlled study assigned participants in a 1:1 ratio to either the ...
Pan C, Jiang H, Feng Y, Wang S, Zhang J, Wang Z, Zhou Y, Li F, Zhang Z, Li Y, Chen L.   +10 more
europepmc   +2 more sources

Exploring the dipeptidyl peptidase-IV inhibitory potential of probiotic-fermented milk: An in vitro and in silico comprehensive investigation into peptides from milk of different farm animals

Journal of Dairy Science
: Bioactive peptides produced via enzymatic hydrolysis have been widely investigated for their dipeptidyl peptidase-IV (DPP-IV) inhibitory properties.
Priti Mudgil, Chee-Yuen Gan, Pei-Gee Yap, Ali Ali Redha, Reem H. Sultan Alsaadi, Khaja Mohteshamuddin, José E. Aguilar-Toalá, Abraham M. Vidal-Limon, Andrea M. Liceaga, Sajid Maqsood   +9 more
doaj   +1 more source

Effect of empagliflozin on urinary albumin excretion and hypoxic biomarkers in early diabetic kidney disease: A randomised double‐blind, placebo‐controlled trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The precise mechanism of sodium glucose co‐transporter 2 (SGLT2) inhibitor on reno‐protective effect has been still unclear. In this study, we hypothesised that SGLT2 inhibitor prevents diabetic kidney disease via reduction of hypoxia‐induced factors.
Hisashi Makino, Masato Kasahara, Ryuzo Takashima, Shu Kasama, Naoki Ozu, Hyohun Park, Qingxing Chen, Kazuhiko Tsuruya, Mayu Tochiya, Yoko Omura‐Ohata, Tamiko Tamanaha, Michio Noguchi, Takeshi Aiba, Fumiki Yoshihara, Kiminori Hosoda   +14 more
wiley   +1 more source

The Potential Role of Cyclopeptides from Pseudostellaria heterophylla, Linum usitatissimum and Drymaria diandra, and Peptides Derived from Heterophyllin B as Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes: An In Silico Study. [PDF]

Metabolites, 2022
Liao HJ, Tzen JTC.
europepmc   +1 more source

Analgesic and anti-inflammatory effectiveness of sitagliptin and vildagliptin in mice [PDF]

, 2021
Cayasso, Mayella, László, F. János, Pórszász, Róbert, Szalai, Andrea, Ujhelyi, Judit Ágnes, Ujhelyi, Zoltán, Vecsernyés, Miklós   +6 more
core   +1 more source

Az entero-inzularis tengely (dipeptidyl peptidase-4-incretin rendszer) jelentősége diabetesben és különböző kóros glükóztoleranciával járó állapotokban = Significance of the entero-insular axis (dipeptidyl peptidase-4–incretin system) in diabetes and in various conditions with impaired glucose tolerance [PDF]

, 2011
• Az éhomi szérum DPP-4 aktivitás nem magasabb 2-es típusú cukorbetegekben (T2DM), ha –klinikailag a nem alkoholos zsírmájbetegséget (NAFLD) a csoportból kizárjuk.
Firneisz, Gábor
core  

Exploring the clinical utility of DPP-IV and SGLT2 inhibitors in papillary thyroid cancer: a literature review

Frontiers in Pharmacology
In the realm of clinical management, Papillary Thyroid Cancer (PTC) stands out as a prevalent thyroid malignancy, characterized by significant metabolic challenges, particularly in the context of carbohydrate metabolism.
Angelika Buczyńska, Maria Kościuszko, Adam Jacek Krętowski, Adam Jacek Krętowski, Anna Popławska-Kita   +4 more
doaj   +1 more source